Evidence map›Paper›PMID 35941537›Full record

ArticleBMC gastroenterology2022

The upregulation of stromal antigen 3 expression suppresses the phenotypic hallmarks of hepatocellular carcinoma through the Smad3-CDK4/CDK6-cyclin D1 and CXCR4/RhoA pathways.

Menglin Zhao, Yanyan Wang, Yue Zhang, Xinwei Li, Jiaqi Mi, Qiang Wang, Zhijun Geng, Lugen Zuo, Xue Song, Sitang Ge and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. The mitotic STAG3-cohesin complex shapes male germline nucleome.Nature structural & molecular biology · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Menglin Zhao *Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China.
Yanyan Wang *Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China.
Yue ZhangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China.
Xinwei LiDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China.
Jiaqi MiDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China.
Qiang WangDepartment of Network Information Center, Bengbu Medical College, No. 2600 Donghai Road, Bengbu, 233030, Anhui, China.
Zhijun GengDepartment of Central Laboratory, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Lugen ZuoDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China.
Xue SongDepartment of Central Laboratory, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Sitang GeDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China.
Zining ZhangDepartment of Clinical Medicine Science, Bengbu Medical College, No. 2600 Donghai Road, Bengbu, 233030, Anhui, China.
Mingyue TangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China.
Huiyuan LiDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China.
Zishu WangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China.
Chenchen JiangCancer Neurobiology Group, School of Medicine & Public Health, The University of Newcastle, Callaghan, NSW, 2308, Australia. chenchen.jiang@newcastle.edu.au.
Fang SuDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Bengbu, 233030, Anhui, China. sufang2899@163.com.
First Affiliated Hospital of Bengbu Medical College · CNBengbu Medical College · CNUniversity of Newcastle Australia · AU

Funding

512 Talent Cultivation Plan of Bengbu Medical College by51201319, by51201107Research and Innovation Team of Bengbu Medical College BYKC201908, BYKC201909Science and Technology Development Fund Project of Bengbu Medical College BYKF1846Support Program for Outstanding Young Talents in Colleges and Universities of Anhui Province gxyq2018038the College Student Innovation Training Program of Bengbu Medical College Byycx1927the College Student Innovation Training Program of Bengbu Medical College Byycx20045the National Natural Science Foundation of China 81702450
6 · The paper itself

Abstract

backgroundThe stromal antigen 3 (STAG3) gene encodes an adhesion complex subunit that can regulate sister chromatid cohesion during cell division. Chromosome instability caused by STAG3 gene mutation may potentially promote tumor progression, but the effect of STAG3 on hepatocellular carcinoma (HCC) and the related molecular mechanism are not reported in the literature. The mechanism of the occurrence and development of HCC is not adequately understood. Therefore, the biological role of STAG3 in HCC remains to be studied, and whether STAG3 might be a sensitive therapeutic target in HCC remains to be determined.

methodsThe expression and clinical significance of STAG3 in HCC tissues and cell lines were determined by RT-qPCR and immunohistochemistry analyses. The biological functions of STAG3 in HCC were determined through in vitro and in vivo cell function tests. The molecular mechanism of STAG3 in HCC cells was then investigated by western blot assay.

resultsThe mRNA expression of STAG3 was lower in most HCC cells than in normal cells. Subsequently, an immunohistochemical analysis of STAG3 was performed with 126 samples, and lower STAG3 expression was associated with worse overall survival in HCC patients. Moreover, cytofunctional tests revealed that the lentivirus-mediated overexpression of STAG3 in HCC cells inhibited cell proliferation, migration, and invasion; promoted apoptosis; induced G1/S phase arrest in vitro; and inhibited tumor growth in vivo. Furthermore, studies of the molecular mechanism suggested that the overexpression of STAG3 increased Smad3 expression and decreased CDK4, CDK6, cyclin D1, CXCR4 and RhoA expression.

conclusionSTAG3 exhibits anticancer effects against HCC, and these effects involve the Smad3-CDK4/CDK6-cyclin D1 and CXCR4/RhoA pathways. STAG3 is a tumor-suppressor gene that may serve as a potential target for molecular therapy, which provides a new idea for the treatment of HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCell Cycle ProteinsCell Line, TumorCell ProliferationCyclin D1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Gene Expression Regulation, NeoplasticHumansReceptors, CXCR4rhoA GTP-Binding ProteinSmad3 ProteinUp-RegulationCDK4 protein, humanCDK6 protein, humanCell Cycle ProteinsCXCR4 protein, humanCyclin D1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Receptors, CXCR4rhoA GTP-Binding ProteinRHOA protein, humanSmad3 ProteinSMAD3 protein, humanSTAG3 protein, humanApoptosisCell cycleHepatocellular carcinomaInvasionMigrationProliferationStromal antigen 3

Identifiers

PMID35941537
PMCPMC9361574
OpenAlexW4290648368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.